Drugs / AZD4785
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03101839 | May 2017 → Jan 2019 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4785 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03101839 ↗ |
| Known as | ION-651987 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297900 ↗ |
| Known as | IONIS-KRAS-2.5RX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297900 ↗ |
| Modality | Antisense oligonucleotide | “KRAS Antisense Oligonucleotide” NCT03101839 ↗ |
| Route | Intravenous | “AZD4785 will be given as an IV infusion over 1 hour” NCT03101839 ↗ |
| Target | KRAS | “KRAS Antisense Oligonucleotide” NCT03101839 ↗ |